Celltrion Pharm, Inc. (KOSDAQ:068760)
South Korea · Delayed Price · Currency is KRW 68,100
-1,600 (-2.30%)
At close: Feb 6, 2026
Celltrion Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
Period Ending | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
Operating Revenue | 274,731 | 233,568 | 173,513 | 146,880 | 135,860 | 104,811 |
Other Revenue | - | - | 0 | - | -0 | -0 |
| 274,731 | 233,568 | 173,513 | 146,880 | 135,860 | 104,811 | |
Revenue Growth (YoY) | 53.21% | 34.61% | 18.13% | 8.11% | 29.62% | 40.25% |
Cost of Revenue | 193,889 | 160,635 | 111,274 | 106,508 | 77,772 | 62,948 |
Gross Profit | 80,842 | 72,933 | 62,239 | 40,372 | 58,088 | 41,863 |
Selling, General & Admin | 43,542 | 41,106 | 41,870 | 31,904 | 46,272 | 41,220 |
Research & Development | 5,730 | 4,612 | 2,132 | 1,919 | 1,033 | 13,266 |
Amortization of Goodwill & Intangibles | 184.04 | 251.86 | 395.5 | 405.19 | 410.74 | 427.03 |
Other Operating Expenses | 1,863 | 1,792 | 1,564 | 1,427 | 1,287 | 1,146 |
Operating Expenses | 51,956 | 49,302 | 47,500 | 37,206 | 49,475 | 56,948 |
Operating Income | 28,885 | 23,631 | 14,739 | 3,166 | 8,613 | -15,085 |
Interest Expense | -4,645 | -4,583 | -5,244 | -5,965 | -5,475 | -8,459 |
Interest & Investment Income | 331.11 | 323.72 | 274.92 | 606.53 | 96.78 | 109.28 |
Currency Exchange Gain (Loss) | 538.96 | 613.52 | -119.79 | -37.47 | 61.66 | 17.4 |
Other Non Operating Income (Expenses) | 67.27 | 168.3 | -40.73 | -124.22 | 12,168 | -32.26 |
EBT Excluding Unusual Items | 25,177 | 20,153 | 9,609 | -2,354 | 15,464 | -23,450 |
Gain (Loss) on Sale of Assets | -25.64 | -25.64 | -458.61 | -3.36 | - | - |
Asset Writedown | - | - | -305.6 | -3,902 | - | - |
Pretax Income | 25,152 | 20,128 | 8,845 | -6,260 | 15,464 | -23,450 |
Income Tax Expense | -873.97 | -811.83 | 242.68 | 3,129 | -251.21 | -2,344 |
Net Income | 26,026 | 20,940 | 8,602 | -9,389 | 15,715 | -21,106 |
Net Income to Common | 26,026 | 20,940 | 8,602 | -9,389 | 15,715 | -21,106 |
Net Income Growth | 146.81% | 143.42% | - | - | - | - |
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 37 |
Shares Outstanding (Diluted) | 45 | 45 | 44 | 44 | 44 | 37 |
Shares Change (YoY) | 0.23% | 0.18% | 0.40% | 1.38% | 18.02% | 33.27% |
EPS (Basic) | 586.55 | 471.92 | 193.93 | -211.88 | 359.53 | -569.87 |
EPS (Diluted) | 583.36 | 469.96 | 193.47 | -211.89 | 359.53 | -569.87 |
EPS Growth | 146.02% | 142.92% | - | - | - | - |
Free Cash Flow | -2,181 | -5,731 | -2,633 | 7,106 | -11,242 | -28,294 |
Free Cash Flow Per Share | -48.89 | -128.59 | -59.18 | 160.36 | -257.21 | -763.96 |
Gross Margin | 29.43% | 31.23% | 35.87% | 27.49% | 42.76% | 39.94% |
Operating Margin | 10.51% | 10.12% | 8.49% | 2.15% | 6.34% | -14.39% |
Profit Margin | 9.47% | 8.96% | 4.96% | -6.39% | 11.57% | -20.14% |
Free Cash Flow Margin | -0.79% | -2.45% | -1.52% | 4.84% | -8.28% | -27.00% |
EBITDA | 42,796 | 37,101 | 27,761 | 15,878 | 20,847 | -3,016 |
EBITDA Margin | 15.58% | 15.88% | 16.00% | 10.81% | 15.34% | -2.88% |
D&A For EBITDA | 13,911 | 13,470 | 13,023 | 12,712 | 12,234 | 12,069 |
EBIT | 28,885 | 23,631 | 14,739 | 3,166 | 8,613 | -15,085 |
EBIT Margin | 10.51% | 10.12% | 8.49% | 2.15% | 6.34% | -14.39% |
Effective Tax Rate | - | - | 2.74% | - | - | - |
Advertising Expenses | - | 2,198 | 3,659 | 3,174 | 4,316 | 9,281 |
Updated May 14, 2021. Source: S&P Global Market Intelligence. Standard template. Financial Sources.